

DMB

Display Date	9-21-99
Publication Date	9-22-99
Certifier	MABryant

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

**Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice

---

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

*Name of Committee:* Cardiovascular and Renal Drugs Advisory Committee.

*General Function of the Committee:* To provide advice and recommendations to the agency on FDA's regulatory issues.


*Date and Time:* The meeting will be held on October 14, 1999, 9 a.m. to 5:30 p.m., and October 15, 1999, 9 a.m. to 5 p.m.

*Location:* National Institutes of Health, Clinical Center, Bldg. 10, Jack Masur Auditorium, 9000 Rockville Pike, Bethesda, MD. Parking in the Clinical Center is reserved for Clinical Center patients and their visitors. If you must drive, please use an outlying lot such as Lot 41B. Free shuttle bus service is provided from Lot 41B to the Clinical Center every 8 eight minutes during rush hour and every 15 minutes at other times.

*Contact Person:* Joan C. Standaert, Center for Drug Evaluation and Research (HFD-110), Food and Drug Administration, 5630 Fishers Lane, Rockville, MD 20857, 419-259-2511, or John M. Treacy, 301-827-7001, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12533. Please call the Information Line for up-to-date information on this meeting. Current information may also be accessed on the Internet at the FDA Website "www.fda.gov".

*Agenda:* On October 14, 1999, the committee will discuss acute coronary syndromes. On October 15, 1999, the committee will discuss new drug application 20-967, Simdax® (Levosimendan, Orion Corp.), for the intravenous treatment of patients with decompensated heart failure, in conjunction with conventional therapy.

*Procedure:* Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by October 7, 1999. Oral presentations from the public will be scheduled on October 14, 1999, between approximately 9 a.m. and 10 a.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before October 7, 1999, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the



approximate time requested to make their presentation.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: September 13, 1999

*Gyda A. Suydam*

[FR Doc. 99-???? Filed ??-??-99; 8:45 am]

BILLING CODE 4160-01-F

CERTIFIED TO BE A TRUE COPY OF THE ORIGINAL  
*M. Boyer*